|
JP4878664B2
(ja)
*
|
1996-12-24 |
2012-02-15 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
安定な液体インターフェロン処方物
|
|
US20030190307A1
(en)
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
|
CA2304808C
(en)
*
|
1997-09-23 |
2011-03-22 |
Michael Tschope |
Liquid interferon-.beta. formulations
|
|
KR100767473B1
(ko)
*
|
1999-05-31 |
2007-10-17 |
미쯔비시 가가꾸 가부시끼가이샤 |
간실질세포 증식인자 동결건조 제제
|
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
|
AR034749A1
(es)
*
|
2001-07-09 |
2004-03-17 |
Schering Ag |
Formulaciones de interferon beta humano
|
|
AU2002351756A1
(en)
|
2001-12-21 |
2003-07-15 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
|
EP1475098B1
(en)
*
|
2002-01-18 |
2015-08-05 |
Asahi Kasei Pharma Corporation |
High-concentration preparation of soluble thrombomodulin
|
|
PT1517698E
(pt)
|
2002-06-21 |
2014-11-19 |
Novo Nordisk Healthcare Ag |
Composições sólidas estabilizadas de polipéptidos do fator viia
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7897734B2
(en)
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
TWI272948B
(en)
|
2003-05-01 |
2007-02-11 |
Ares Trading Sa |
HSA-free stabilized interferon liquid formulations
|
|
AR044302A1
(es)
*
|
2003-05-13 |
2005-09-07 |
Ares Trading Sa |
Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
|
|
KR20060015574A
(ko)
|
2003-05-23 |
2006-02-17 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
용액 중 단백질 안정화
|
|
CN1318087C
(zh)
*
|
2003-06-06 |
2007-05-30 |
北京三诺佳邑生物技术有限责任公司 |
去白蛋白神经生长因子制剂
|
|
ES2574581T3
(es)
|
2003-08-14 |
2016-06-20 |
Novo Nordisk Health Care Ag |
Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
|
|
BRPI0416042A
(pt)
*
|
2003-11-13 |
2007-01-02 |
Alza Corp |
composição e aparelho para suprimento transdérmico
|
|
EP1532983A1
(en)
*
|
2003-11-18 |
2005-05-25 |
ZLB Bioplasma AG |
Immunoglobulin preparations having increased stability
|
|
RU2373953C2
(ru)
|
2003-12-19 |
2009-11-27 |
Ново Нордиск Хелс Кеа Аг |
Стабилизированная композиция, содержащая полипептид фактора vii
|
|
EP1750750B1
(en)
*
|
2004-06-01 |
2012-02-01 |
Ares Trading S.A. |
Method of stabilizing proteins
|
|
CN101022822B
(zh)
*
|
2004-08-24 |
2012-06-27 |
第一三共株式会社 |
生理学活性肽的液体制剂
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
PT1809662E
(pt)
*
|
2004-11-10 |
2009-02-26 |
Novartis Vaccines & Diagnostic |
Interferão beta desamidado
|
|
PT1845925T
(pt)
|
2005-01-12 |
2016-11-22 |
Biogen Ma Inc |
Método para distribuir interferão-beta
|
|
CA2593112A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Alza Corporation |
Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
|
|
EP1899462B1
(en)
|
2005-07-02 |
2011-03-09 |
Arecor Limited |
Stable aqueous systems comprising proteins
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
KR101452915B1
(ko)
|
2006-05-04 |
2014-10-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
다형태
|
|
PT2868315T
(pt)
*
|
2007-12-04 |
2017-09-04 |
Remedy Pharmaceuticals Inc |
Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
|
|
BRPI0821029A2
(pt)
|
2007-12-20 |
2015-06-16 |
Merck Serono Sa |
Fomulações de peg-interferon-beta
|
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
WO2009133408A2
(en)
|
2008-05-01 |
2009-11-05 |
Arecor Limited |
Protein formulation
|
|
EP2328607A1
(en)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
CA2736421A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
|
DE102008051574A1
(de)
|
2008-10-14 |
2010-04-15 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verfahren zur Herstellung von Interferon-beta und deren Varianten
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
|
DE102009032179A1
(de)
|
2009-07-07 |
2011-01-13 |
Biogenerix Ag |
Verfahren zur Reinigung von Interferon beta
|
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
|
DK2531218T3
(en)
|
2010-02-04 |
2019-04-01 |
Csl Behring Ag |
immunoglobulin
|
|
EP2361636A1
(en)
|
2010-02-26 |
2011-08-31 |
CSL Behring AG |
Immunoglobulin preparation and storage system for an immunoglobulin preparation
|
|
DE102010011430A1
(de)
*
|
2010-03-15 |
2011-09-15 |
Kurt Koch |
Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
|
|
CA3070513C
(en)
|
2010-05-05 |
2023-01-03 |
Boehringer Ingelheim International Gmbh |
A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
|
|
KR20130093012A
(ko)
|
2010-06-24 |
2013-08-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
당뇨병 요법
|
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
|
EP2649993B1
(en)
|
2010-12-09 |
2017-04-05 |
Maruishi Pharmaceutical Co., Ltd. |
Stabilizer of acetaminophen
|
|
AU2012229104B2
(en)
|
2011-03-15 |
2017-03-16 |
Biogen Ma Inc. |
Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
|
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
JP2015515480A
(ja)
*
|
2012-04-19 |
2015-05-28 |
シー・アール・バード・インコーポレーテッドＣ Ｒ Ｂａｒｄ Ｉｎｃｏｒｐｏｒａｔｅｄ |
エチレンオキシド滅菌下のｐＨ安定性が改善された注入液
|
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
|
WO2013171166A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
ITMI20120913A1
(it)
*
|
2012-05-28 |
2013-11-29 |
Nicoletta Maxia |
Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
|
|
CN103143000B
(zh)
*
|
2013-03-07 |
2014-11-05 |
安徽安科生物工程（集团）股份有限公司 |
一种重组人干扰素α2b制剂
|
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
|
JP2014208669A
(ja)
*
|
2014-06-17 |
2014-11-06 |
株式会社スリー・ディー・マトリックス |
タンパク質の凝集抑制剤
|
|
ES2825704T3
(es)
|
2014-12-03 |
2021-05-17 |
Csl Behring Ag |
Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
|
|
EP4233840A3
(en)
|
2016-06-10 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
|
KR101943160B1
(ko)
*
|
2016-10-06 |
2019-01-30 |
에이비온 주식회사 |
인터페론 베타 변이체의 안정화 제제
|
|
IL272773B2
(en)
|
2017-08-22 |
2024-06-01 |
Biogen Ma Inc |
Pharmaceutical preparations containing anti-amyloid cell antibodies
|
|
KR102731889B1
(ko)
*
|
2019-07-18 |
2024-11-19 |
에이비온 주식회사 |
2당화된 인터페론-베타 단백질의 정제 방법
|
|
CN110714051B
(zh)
*
|
2019-11-20 |
2023-04-07 |
迈克生物股份有限公司 |
蛋白c活性测定试剂盒
|
|
MX2022013662A
(es)
*
|
2020-04-29 |
2023-02-01 |
Abion Inc |
Variante del interferon-beta humano con doble mutacion y metodo para mejorar la estabilidad de la variante del interferon-beta humano.
|
|
WO2022207655A1
(en)
*
|
2021-03-30 |
2022-10-06 |
Schott Schweiz Ag |
System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
|
|
CN114177273B
(zh)
*
|
2021-11-29 |
2024-05-28 |
苏州人本药业有限公司 |
一种含有神经毒素的液体制剂及其制备方法
|
|
AU2022426492A1
(en)
*
|
2021-12-27 |
2024-07-18 |
Enalare Therapeutics Inc. |
Respiratory stimulant parenteral formulations
|